Crohn’s Disease Trials

Study Title:

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects With Moderately to Severely Active Crohn’s Disease.

Study Title:

Evaluation of the response of itraconazole and terbinafine therapy in subjects with Crohn’s disease not responding adequately to current therapy (CD-IT)

Study Title:
A Multicenter Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn’s Disease Who Responded to Induction Treatment in M16-006 or M15-991.

Study Title:
A Multicenter, Randomized, Double-Blind, Placebo Controlled Maintenance and Long Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn’s Disease who completed the M14-431 or M14-433 Studies.

Study Title:

A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn’s Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks

Study title:
A phase 3, randomized, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of guselkumab in participants with fistulizing, perianal Crohn’s Disease

Study title:

A Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants with Crohn’s Disease After Surgical Resection

Study title:

A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn’s Disease

Study title:

A 52-Week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn’s Disease

Study title:

The evaluation of injection site pain and adherence in patients switching from a low to high concentration Adalimumab (AVT-02) across multiple indications.

Study title:

Proactive infliximab optimization using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: The OPTIMIZE Trial